[
  {
    "ts": "2025-11-29T00:46:22+00:00",
    "headline": "Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences' (GILD) Global Healthcare Narrative?",
    "summary": "Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for HIV prevention to Eswatini and Zambia, marking a significant step in global access initiatives for this therapy. This move highlights Gilead’s ability to rapidly bring innovative HIV prevention to regions with high disease burden, fostering global health partnerships and expanding its reach in emerging markets. We'll now explore how Gilead's expanded...",
    "url": "https://finance.yahoo.com/news/expanding-lenacapavir-access-africa-reshape-004622353.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3bfcba91-cf65-34bf-ae41-83bf2a8417ef",
      "content": {
        "id": "3bfcba91-cf65-34bf-ae41-83bf2a8417ef",
        "contentType": "STORY",
        "title": "Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences' (GILD) Global Healthcare Narrative?",
        "description": "",
        "summary": "Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for HIV prevention to Eswatini and Zambia, marking a significant step in global access initiatives for this therapy. This move highlights Gilead’s ability to rapidly bring innovative HIV prevention to regions with high disease burden, fostering global health partnerships and expanding its reach in emerging markets. We'll now explore how Gilead's expanded...",
        "pubDate": "2025-11-29T00:46:22Z",
        "displayTime": "2025-11-29T00:46:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/expanding-lenacapavir-access-africa-reshape-004622353.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/expanding-lenacapavir-access-africa-reshape-004622353.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-29T18:09:14+00:00",
    "headline": "Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 while maintaining the stock’s Outperform rating. The firm cited a number of factors for the adjustment, including a longer exclusivity period for Biktarvy, with […]",
    "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-outlook-180914018.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "af139308-0e00-30e7-8553-3dc0d35aa85c",
      "content": {
        "id": "af139308-0e00-30e7-8553-3dc0d35aa85c",
        "contentType": "STORY",
        "title": "Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 while maintaining the stock’s Outperform rating. The firm cited a number of factors for the adjustment, including a longer exclusivity period for Biktarvy, with […]",
        "pubDate": "2025-11-29T18:09:14Z",
        "displayTime": "2025-11-29T18:09:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107",
          "originalWidth": 240,
          "originalHeight": 160,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mRO6Vt56QsZVpg163jv5EQ--~B/aD0xNjA7dz0yNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107.cf.webp",
              "width": 240,
              "height": 160,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zAmBXhGzahEZsMNHkCwDog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-outlook-180914018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-outlook-180914018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]